HOME >> BIOLOGY >> NEWS
Experimental therapy stops allergic reactions in mice

Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) have devised a new, experimental approach to treating allergic diseases. In mice, the scientists used a genetically engineered molecule to connect two receptors on the key immune system cells that cause allergic reactions. Cross-linking these receptor molecules short-circuited the type of allergic reaction that leads to asthma, allergic rhinitis, and even the potentially deadly anaphylaxis caused by food allergy.

This work represents an entirely new approach to treating allergic diseases, says NIAID Director Anthony S. Fauci, M.D. The prevalence of allergic disease has increased significantly in recent decades, and there simply are not many promising therapeutic strategies out there. We hope that NIAIDs continued support of research into the mechanisms of allergy will lead to other innovative concepts like this one.

This research does what science is supposed to do, says Marshall Plaut, M.D., chief of NIAIDs Allergic Mechanisms Section. The researchers succeeded in translating a scientific observation into a clever therapeutic idea. Details of this work, performed by a team of scientists at the University of California at Los Angeles (UCLA) and the University of New Mexico, appear in the May issue of Nature Medicine.

The scientists designed and created a molecule called GE2 that acts on two types of immune system cells central to allergic reactions: mast cells and basophils. In people with allergies, these cells respond to ordinarily harmless substances, such as pollen or peanut proteins, by releasing chemicals such as histamine that trigger the symptoms of allergic reactions. Histamine, for example, causes swelling, sneezing, itching, and irritation.

GE2 binds to receptor molecules on mast cells and basophils that control the release of histamine. One of these receptor molecules is like a gas pedal: it makes the allergic reaction go.
'"/>

Contact: Jeff Minerd
jminerd@niaid.nih.org
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
30-Apr-2002


Page: 1 2

Related biology news :

1. Experimental drug shown to block mutant protein causing blood disease
2. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
3. Experimental smallpox vaccine protects against monkeypox in nonhuman primates
4. Experimental Biology 2004 - Translating the Genome
5. Experimental Biology 2004 meets in Washington, D.C. April 17-21
6. Experimental hantavirus vaccine elicits strong antibody response in primates
7. Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental Biology 2003 meets in San Diego April 11-15
10. Experimental gene switch increases lifespan with no ill effects
11. APS awards 44 minority travel fellowships to the Experimental Biology 2002 meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2018)... ... December 04, 2018 , ... ... the much-anticipated launch of their 100-liter (26 gallon) SAFEthread Drum. The 100-liter ... in 2017, which brought a much-needed modern redesign to the plastic drums being ...
(Date:11/29/2018)... ... November 29, 2018 , ... ACEA ... the new NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT). ... develop transformative tools and technologies for the consistent, scalable and low-cost production of ...
(Date:11/27/2018)... ... November 26, 2018 , ... uBiome, ... Founder of the website IBDwatch and Gastroenterology Fellow at the University of Louisville, ... from around the world, Dr. Wuerth will bring to uBiome knowledge and research ...
Breaking Biology News(10 mins):
(Date:11/20/2018)... ... 20, 2018 , ... Each year Forbes receives thousands of nominations for candidates ... performance by individuals under 30 years of age. The Forbes 30 Under 30 list ... Entertainment to Venture Capital and Science. , In 2017, Visikol CEO Dr. Michael ...
(Date:11/15/2018)... ... November 14, 2018 , ... ... first self-learning snore-reduction mask to the public. It is estimated that 90 ... sleep for themselves and their partner. The resulting daytime fatigue causes extreme difficulty ...
(Date:11/13/2018)... (PRWEB) , ... November 12, 2018 , ... ... to reduce stethoscope contamination that two large U.S. studies, published last week, confirm ... the American Journal of Infection Control (AJIC) conclude that stethoscopes are often improperly ...
(Date:11/13/2018)... BOSTON (PRWEB) , ... November 13, 2018 , ... ... an analysis of the spine technology market last week that asserts it is ... global patient population. , Humad’s analysis describes market consolidation, pricing pressure ...
Breaking Biology Technology:
Cached News: